参芪扶正液抗蒽环类化疗药物所致心脏毒性的作用-东南大学学报医学版

参芪扶正液抗蒽环类化疗药物所致心脏毒性的作用

单位：东南大学附属中大医院肿瘤科,江苏南京,210009

分类号：R453, R733.4

出版年·卷·期（页码）：2008·27·第五期（375-377）

摘要：

目的:观察参芪扶正液抗蒽环类药物化疗所致心脏毒性的作用.方法:80例恶性淋巴瘤患者随机分为治疗组和对照组,治疗组在应用蒽环类药物化疗同时给予参芪扶正液静脉点滴,对照组单用化疗药物,观察两组患者在化疗过程中的心脏毒性反应和心功能的变化情况.结果:治疗组仅1例出现急性心脏毒性反应,发生率为2.5%,而对照组有6例,发生率为15%,明显高于治疗组(P<0.05).两组治疗前LVEF无明显差异,化疗后对照组较治疗组下降27.9%,P<0.01.对照组的血清肌钙蛋白水平在各个时段均高于治疗组(P<0.05),并随着化疗时间的延长而逐渐增高.结论:参芪扶正液在蒽环类药物化疗过程中具有心脏保护作用,是较好的心肌细胞保护剂.

Objective To observe the heart protection effect of parenteral solution Shenqifuzheng in the chemotherapy with marcellomycin.Methods 80 patients were divided into two groups :treatment group and control group.The patients in the treatment group were given parenteral solution Shenqifuzheng and chemotherapy with marcellomycin,while the patients in the control group were only given chemotherapy.Results 1(2.5%) case had acute cardiac toxic reaction in the treatment group and 6(15%) cases in the control group.The incidence rate in the control group was higher than that in the treatment group(P<0.05).LVEF 27.9% decreased in the control group,while no change in the treatment group.The levels of troponin increased in the control group more than that in the treatment group,and increased gradually with chemotherapy.Conclusion Parenteral solution Shenqifuzheng can protect heart in the chemotherapy with marcellomycin,it’s a good myocardial cellular protectant.

参考文献：

[1] 周际昌. 实用肿瘤内科学, 2003
[2] DORSHOOW J H. Doxorubicin induced cardiac toxity, 1991
[3] Italian Multicentre Trial. Phase Ⅲ randomized study of fluorouracil,epirubicin and cyclophosphamide vs fluorouracil,doxorubicin,and cyclophosphamide in advanced breast cancer, 1988
[4] GREEN D M, GRIGORIVE Y A, NAN B. Congestive heart failure after treatment for Wilm's tumor:a report form the National Wilm's Tumor Study group. 2001(7)
[5] MERTENS A C, YASUI Y, NEGLIA JP. Late mortality experience in five-year surivors of childhood and adolescent cancer:the chlidhood cancer surivor study. 2001(13)
[6] MARTONI A, MELOTTI B, GUARALDI M. High-dose epirubicin for untreated patients with advanced tumors:a phase Ⅰ study. 1990. doi:10.1016/0277-5379(90)90270-4
[7] HABESHAW T, PUAL J, JONES R. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer:the results of a randomized trial, 1991(2)
[8] FOCAN C, ANDRIEN J M, CLOSON M T. Dose-response relationship of epirubicin based first-line chemotherapy for advanced breast cancer, 1993(7)
[9] 邓俊, 刘雪萍. 参芪扶正注射液治疗顽固性心衰的临床研究, 2004
[10] 黄景玉. 参麦注射液防治化疗药所致急性心脏损伤临床观察. 中国中医急症2004(7). doi:10.3969/j.issn.1004-745X.2004.07.019
[11] 廖子君, 余国政, 陈晓泉. 抗肿瘤细胞毒药物所致心脏毒性发生机制及处理对策. 临床肿瘤学杂志2004(9). doi:10.3969/j.issn.1009-0460.2004.04.038

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录